Form: 3

Initial statement of beneficial ownership of securities

April 1, 2020

Documents

FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  D'Alvise Janelle
 2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2020		 3. Issuer Name and Ticker or Trading Symbol
Acasti Pharma Inc. [ACST]
(Last)
(First)
(Middle)
C/O ACASTI PHARMA INC., 545 PROMENADE DU CENTROPOLIS, SUITE 100		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
PRESIDENT & CEO
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

LAVAL, A8 H7T 0A3		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Shares 52,500
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (Right to Buy)   (1) 05/12/2023 Common Shares 525,000 $ 1.56 (8) D  
Share Option (Right to Buy)   (2) 06/14/2027 Common Shares 258,000 $ 1.77 (8) D  
Share Option (Right to Buy)   (3) 06/14/2027 Common Shares 172,000 $ 1.77 (8) D  
Share Option (Right to Buy)   (4) 07/02/2028 Common Shares 906,248 $ 0.77 (8) D  
Share Option (Right to Buy)   (5) 04/15/2029 Common Shares 226,100 $ 1.28 (8) D  
Share Option (Right to Buy)   (6) 04/15/2029 Common Shares 771,900 $ 1.28 (8) D  
Share Option (Right to Buy)   (7) 03/31/2030 Common Shares 1,335,000 $ 0.53 (8) D  
Warrants 02/21/2017 02/21/2022 Common Shares 26,250 $ 2.15 (8) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
D'Alvise Janelle
C/O ACASTI PHARMA INC.
545 PROMENADE DU CENTROPOLIS, SUITE 100
LAVAL, A8 H7T 0A3		   X     PRESIDENT & CEO  

Signatures

/s/ Kelsey Weiner, Attorney-in-Fact 04/01/2020
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents 525,000 common shares underlying 525,000 share options granted on May 12, 2016. These share options vested in 12 equal installments on a quarterly basis starting from May 12, 2016 until May 12, 2019.
(2) Represents 258,000 common shares underlying 258,000 share options granted on June 14, 2017. These share options vest in 12 equal installments on a quarterly basis starting from June 14, 2017 until June 14, 2020.
(3) Represents 172,000 common shares underlying 172,000 share options granted on June 14, 2017. These share options vest in 12 equal installments on a quarterly basis starting from June 14, 2017 until June 14, 2020.
(4) Represents 906,248 common shares underlying 906,248 share options granted on July 2, 2018. These share options vest in 12 equal installments on a quarterly basis starting from July 2, 2018 until July 2, 2021.
(5) Represents 226,100 common shares underlying 226,100 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022.
(6) Represents 771,900 common shares underlying 771,900 share options granted on April 15, 2019. These share options vest in 12 equal installments on a quarterly basis starting from April 15, 2019 until April 15, 2022.
(7) Represents 1,335,000 common shares underlying 1,335,000 share options granted on March 31, 2020. These share options vest in 12 equal installments on a quarterly basis starting from March 31, 2020 until March 31, 2023.
(8) Canadian dollars.
 
Remarks:
Exhibit List - Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.